Skip To Main Content

Investors & Media

Company Overview
View All

LyGenesis’s cell therapies are engrafted using endoscopic ultrasound procedure, which is associated with decreased medical risks and costs relative to full organ transplantation. Our pipeline of therapies target a variety of unmet needs, including end stage liver disease, Type 1 diabetes, end stage renal disease, aging, and autoimmune disorder.

Insights Corner

LyGenesis is Pioneering Organ Regeneration in Pittsburgh

Pittsburgh Region Video Jul 26, 2021

Lygenesis, a University of Pittsburgh life sciences spinout, is using cell therapy technology to transform the methodology behind the science of organ transplantation, thanks to experts like Michael Hufford.